At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 167 enrolled
Drug / intervention
TAP-144-SR(6M) +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 3 Comparative Study of TAP-144-SR(6M) in Postoperative and Hormone Therapy-naïve Patients With Premenopausal Breast Cancer
In Brief
A Phase 3 clinical trial evaluating TAP-144-SR(6M) and TAP-144-SR(3M) for Premenopausal Breast Cancer. Completed, enrolled 167 participants across 15 sites.
Detailed Summary
Hormone dynamics, pharmacokinetics, safety, and efficacy of TAP-144-SR(6M) will be evaluated against TAP-144-SR(3M) in postoperative and hormone therapy-naïve patients with premenopausal breast cancer
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsPremenopausal Breast Cancer
CountriesJapan
Collaborators--
Timeline
Phase 3CompletedFinished
201220132014201520162017201820192020202120222023202420252026
First PostedMar 2012
Enrollment StartApr 2012
Primary CompletionDec 2014
TodayJul 2026
First PostedMar 7, 2012
Enrollment StartApr 1, 2012
Primary CompletionDec 1, 2014
TodayJul 2, 2026
Enrollment to primary: 2.7 yearsPosted 14.3 years ago
Interventions
TAP-144-SR(6M)drug
TAP-144-SR(3M)drug